- Home
- CLM vs MESO Comparison
CLM vs MESO Comparison
Compare CLM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLM | MESO |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CLM | MESO |
|---|---|---|
| Price | $6.24 | $13.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | ★ 2.9M | 255.3K |
| Earning Date | 01-01-0001 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $51.63 |
| Revenue Next Year | N/A | $63.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.56 | $11.89 |
| 52 Week High | $8.53 | $21.50 |
Technical Indicators
Market Signals| Indicator | CLM | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 46.52 |
| Support Level | $5.56 | $11.89 |
| Resistance Level | $6.45 | $16.03 |
| Average True Range (ATR) | 0.17 | 0.50 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 92.65 | 40.72 |
Price Performance
Historical ComparisonAbout CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.